High-throughput quantification of circulating metabolites improves prediction of subclinical atherosclerosis.

AIMS High-throughput metabolite quantification holds promise for cardiovascular risk assessment. Here, we evaluated whether metabolite quantification by nuclear magnetic resonance (NMR) improves prediction of subclinical atherosclerosis in comparison to conventional lipid testing. METHODS AND RESULTS Circulating lipids, lipoprotein subclasses, and small molecules were assayed by NMR for 1595 individuals aged 24-39 years from the population-based Cardiovascular Risk in Young Finns Study. Carotid intima-media thickness (IMT), a marker of subclinical atherosclerosis, was measured in 2001 and 2007. Baseline conventional risk factors and systemic metabolites were used to predict 6-year incidence of high IMT (≥ 90 th percentile) or plaque. The best prediction of high intima-media thickness was achieved when total and HDL cholesterol were replaced by NMR-determined LDL cholesterol and medium HDL, docosahexaenoic acid, and tyrosine in prediction models with risk factors from the Framingham risk score. The extended prediction model improved risk stratification beyond established risk factors alone; area under the receiver operating characteristic curve 0.764 vs. 0.737, P =0.02, and net reclassification index 17.6%, P =0.0008. Higher docosahexaenoic acid levels were associated with decreased risk for incident high IMT (odds ratio: 0.74; 95% confidence interval: 0.67-0.98; P = 0.007). Tyrosine (1.33; 1.10-1.60; P = 0.003) and glutamine (1.38; 1.13-1.68; P = 0.001) levels were associated with 6-year incident high IMT independent of lipid measures. Furthermore, these amino acids were cross-sectionally associated with carotid IMT and the presence of angiographically ascertained coronary artery disease in independent populations. CONCLUSION High-throughput metabolite quantification, with new systemic biomarkers, improved risk stratification for subclinical atherosclerosis in comparison to conventional lipids and could potentially be useful for early cardiovascular risk assessment.

[1]  Reino Laatikainen,et al.  High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. , 2009, The Analyst.

[2]  Mika Ala-Korpela,et al.  Critical evaluation of 1H NMR metabonomics of serum as a methodology for disease risk assessment and diagnostics , 2008, Clinical chemistry and laboratory medicine.

[3]  Lawrence J Appel,et al.  Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[4]  S. Mora Advanced lipoprotein testing and subfractionation are not (yet) ready for routine clinical use. , 2009, Circulation.

[5]  Brian J. Bennett,et al.  Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease , 2011, Nature.

[6]  Kimmo Kaski,et al.  Detailed metabolic and genetic characterization reveals new associations for 30 known lipid loci. , 2012, Human molecular genetics.

[7]  Luigi Atzori,et al.  Metabolomics as a tool for cardiac research , 2011, Nature Reviews Cardiology.

[8]  J. Lau,et al.  Effects of omega-3 fatty acids on coronary restenosis, intima-media thickness, and exercise tolerance: a systematic review. , 2006, Atherosclerosis.

[9]  M. Tobin,et al.  Coronary Artery Disease–Associated Locus on Chromosome 9p21 and Early Markers of Atherosclerosis , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[10]  Markus Perola,et al.  Metabonomic, transcriptomic, and genomic variation of a population cohort , 2010, Molecular systems biology.

[11]  D. Harrison,et al.  Interactions between L-arginine and L-glutamine change endothelial NO production. An effect independent of NO synthase substrate availability. , 1995, The Journal of clinical investigation.

[12]  Lawrence J Appel,et al.  Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. , 2003, Circulation.

[13]  Michael J Pencina,et al.  Carotid-wall intima-media thickness and cardiovascular events. , 2011, The New England journal of medicine.

[14]  Nancy R Cook,et al.  Advances in Measuring the Effect of Individual Predictors of Cardiovascular Risk: The Role of Reclassification Measures , 2009, Annals of Internal Medicine.

[15]  H. Superko Advanced Lipoprotein Testing and Subfractionation Are Clinically Useful , 2009, Circulation.

[16]  P. Calder,et al.  Cardiovascular effects of marine omega-3 fatty acids , 2010, The Lancet.

[17]  Edward A Dennis,et al.  The human plasma lipidome. , 2011, The New England journal of medicine.

[18]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[19]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[20]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[21]  T. Lehtimäki,et al.  Characterization of systemic metabolic phenotypes associated with subclinical atherosclerosis. , 2011, Molecular bioSystems.

[22]  Svati H Shah,et al.  A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. , 2009, Cell metabolism.

[23]  S. Grundy,et al.  National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .

[24]  Risto Telama,et al.  Cohort profile: the cardiovascular risk in Young Finns Study. , 2008, International journal of epidemiology.

[25]  R. Krauss,et al.  Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. , 1997, Circulation.

[26]  T. Lehtimäki,et al.  Diagnostic performance of plasma high sensitive C‐reactive protein in detecting three‐vessel coronary artery disease: modification by apolipoprotein E genotype , 2008, Scandinavian journal of clinical and laboratory investigation.

[27]  Geoffrey S Ginsburg,et al.  Association of a Peripheral Blood Metabolic Profile With Coronary Artery Disease and Risk of Subsequent Cardiovascular Events , 2010, Circulation. Cardiovascular genetics.

[28]  J. Lau,et al.  Systematic Review: Association of Low-Density Lipoprotein Subfractions With Cardiovascular Outcomes , 2009, Annals of Internal Medicine.

[29]  Terho Lehtimäki,et al.  Conventional Cardiovascular Risk Factors and Metabolic Syndrome in Predicting Carotid Intima-Media Thickness Progression in Young Adults: The Cardiovascular Risk in Young Finns Study , 2009, Circulation.

[30]  Matthias W. Lorenz,et al.  Prediction of Clinical Cardiovascular Events With Carotid Intima-Media Thickness: A Systematic Review and Meta-Analysis , 2007, Circulation.

[31]  D. Levy,et al.  Multiple biomarkers for the prediction of first major cardiovascular events and death. , 2006, The New England journal of medicine.

[32]  T. Laitinen,et al.  Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. , 2003, JAMA.

[33]  D. Lloyd‐Jones,et al.  Cardiovascular risk prediction: basic concepts, current status, and future directions. , 2010, Circulation.

[34]  Samia Mora,et al.  Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women , 2009, Circulation.

[35]  V. Mootha,et al.  Metabolite profiles and the risk of developing diabetes , 2011, Nature Network Boston.

[36]  W D Wagner,et al.  A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. , 1994, Circulation.

[37]  M. Pencina,et al.  Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. , 2009, JAMA.

[38]  T. Laitinen,et al.  Childhood levels of serum apolipoproteins B and A-I predict carotid intima-media thickness and brachial endothelial function in adulthood: the cardiovascular risk in young Finns study. , 2008, Journal of the American College of Cardiology.

[39]  Ian D. Wilson,et al.  Metabolic Phenotyping in Health and Disease , 2008, Cell.

[40]  Thomas J. Wang,et al.  Assessing the Role of Circulating, Genetic, and Imaging Biomarkers in Cardiovascular Risk Prediction , 2011, Circulation.

[41]  Olli Saarela,et al.  Contribution of 30 Biomarkers to 10-Year Cardiovascular Risk Estimation in 2 Population Cohorts: The MONICA, Risk, Genetics, Archiving, and Monograph (MORGAM) Biomarker Project , 2010, Circulation.

[42]  David W. Hosmer,et al.  Applied Logistic Regression , 1991 .